« Back
Home /
SU11274

SU11274

Item no.	M1890-200mg
Manufacturer	AbMole
CASRN	658084-23-2
Amount	200mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer Renal Cancer
Type	Inhibitors
Specific against	other
Purity	>99%
Citations	c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Yu H, et al . Biochem Biophys Res Commun. 2012 Sep 28. PMID: 23026049 . c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Gibney GT, et al . Ann Oncol. 2012 Sep 28. PMID: 23022995 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PKI-SU11274
Similar products	SU11274, PKI-SU11274
Available
Molecular Weight	568, 09
Solubility	DMSO 82 mg/mL
Bioactivity information	SU11274 is a selective c-Met inhibitor (IC50 = 0.01 μM in vitro).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1890-200mg-safety-datasheet.pdf